Arabic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
neoplasm metastasis/tyrosine
يتم حفظ الارتباط في الحافظة
الصفحة 1 من عند 46 النتائج
Phosphatase associated with metastasis
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to the field of cancer diagnostics and therapeutics. In particular it relates to a gene which appears to be significantly associated with the progression of cancer to more advanced stages, including metastasis.
2. Background
Treatment of metastatic disease
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
The present invention relates to diagnosis and treatment of metastatic disease. More particularly, this invention relates to the use of an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells as the target for the diagnosis and treatment of
Method for activating T cell protein tyrosine phosphatase for therapeutic applications
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
This invention relates to a method for activation of T cell protein tyrosine phosphatase (TCPTP) and a method for inhibiting tyrosine kinase signalling in an individual. Further, the invention concerns a method for preventing or treating a disease or disorder in an individual,
Tyrosine alkoxyguanidines as integrin inhibitors
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
The present invention relates to novel tyrosine alkoxyguanidine compounds that are inhibitors of alpha V (.alpha.v) integrins, for example .alpha.v.beta.3 and .alpha.v.beta.5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions
Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase beta/zeta
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
BACKGROUND OF THE INVENTION
Pleiotrophin (PTN) is a platelet-derived growth factor-inducible heparin-binding growth and differentiation factor that signals diverse phenotypes in normal and deregulated cellular growth and differentiation. See Milner, et al., (1989) Biochem. Biophys. Res. Commun. 165,
Keratinocyte growth factor receptor--tyrosine specific inhibitors for the prevention of cancer metastatis
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
BACKGROUND
Current cancer chemotherapy or radiation treatment is designed to kill all rapidly growing cells; thus, resulting in a very high incidence of adverse side effects and toxicity. Further, very few cancer treatments are specifically designed to prevent the metastatic development and
Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD
This disclosure relates to tyrosine kinases, particularly receptor tyrosine kinases with one or more variants. Further, it relates to methods of using these molecules in screens and analyses, including diagnoses, prognoses, and systems for identification and/or selection of pharmaceutical
Inhibition of cell motility, angiogenesis, and metastasis
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
The present invention in general relates to a method of inhibiting cell motility and angiogenesis and treating various diseases in a mammal, and particularly to a method of inhibiting cell motility and angiogenesis induced by the hepatocyte growth factor (HGF). The present
Shp-2 inhibitors and pharmaceutical compositions comprising them
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formulae (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 27, 2017, is named IMM367US1_SL.txt and is 7,866 bytes in size.
FIELD OF THE
Gene therapy for inhibition of angiogenesis
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
The present invention relates to methods of gene therapy for inhibiting angiogenesis associated with tumor growth, inflammation, psoriasis, rheumatoid arthritis, hemangiomas, diabetic retinopathy, angiofibromas, and macular degeneration.
This invention also relates to animal
Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
BACKGROUND OF THE INVENTION
Protein tyrosine kinases (PTKs) comprise a large and diverse class of proteins having enzymatic activity. The PTKs play an important role in the control of cell growth and differentiation (for review, see Schlessinger & Ullhrich, 1992, Neuron 9:383-391).
For example,
Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
The present invention relates to inhibition of growth factor tyrosine kinase receptor activity, particularly inhibition of angiogenesis and related disorders, tumor progression and growth factor related skeletal disorders, by porphyrin and corrole compounds, and to certain
EphA2 as a therapeutic target for cancer
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
The present invention relates to diagnosis and treatment of metastatic disease. More particularly, this invention relates to the use of an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells as the target for the diagnosis and treatment of
EphA2 as a diagnostic target for metastatic cancer
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
FIELD OF THE INVENTION
The present invention relates to diagnosis of metastatic disease. More particularly, this invention relates to reagents that can detect a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. Most particularly, this invention relates to
قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم
- يعمل في 55 لغة
- العلاجات العشبية مدعومة بالعلم
- التعرف على الأعشاب بالصورة
- خريطة GPS تفاعلية - ضع علامة على الأعشاب في الموقع (قريبًا)
- اقرأ المنشورات العلمية المتعلقة ببحثك
- البحث عن الأعشاب الطبية من آثارها
- نظّم اهتماماتك وابقَ على اطلاع دائم بأبحاث الأخبار والتجارب السريرية وبراءات الاختراع
اكتب أحد الأعراض أو المرض واقرأ عن الأعشاب التي قد تساعد ، واكتب عشبًا واطلع على الأمراض والأعراض التي تستخدم ضدها.
* تستند جميع المعلومات إلى البحوث العلمية المنشورة
